Welcome to our dedicated page for Transmedics Group news (Ticker: TMDX), a resource for investors and traders seeking the latest updates and insights on Transmedics Group stock.
TransMedics Group, Inc. (Nasdaq: TMDX) is a medical technology company that focuses on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure. News about TransMedics often centers on its Organ Care System (OCS) warm perfusion platform, the National OCS Program (NOP), and initiatives aimed at increasing donor organ utilization.
Investors and healthcare professionals following TransMedics news can expect updates on financial results, including quarterly earnings announcements and related conference calls, as reflected in the company’s regular press releases and Form 8-K filings. Coverage also includes participation in major healthcare and investor conferences, where management presents the company’s strategy and discusses its transplant-focused technologies and services.
Another key news theme is TransMedics’ expansion of its logistics and service infrastructure. The company has disclosed the acquisition of fixed-wing aircraft for its National OCS Program and has announced a strategic collaboration with Mercedes-Benz Group AG to launch a dedicated organ transplantation ground transportation network in Italy using Mercedes-Benz V-Class vehicles. These developments are presented as part of a broader effort to build an integrated air and ground logistics network around the OCS platform.
TransMedics also issues news related to corporate growth, such as inducement equity grants under Nasdaq Listing Rule 5635(c)(4) and plans for a new global headquarters and integrated campus in Somerville, Massachusetts. For readers tracking TMDX, this news feed provides a centralized view of operational updates, regulatory and financial disclosures referenced in press releases, and developments in the company’s organ transplant technologies and services.
TransMedics Group, Inc. (Nasdaq: TMDX) announced the FDA's postponement of the Advisory Committee meeting regarding its OCS Heart premarket approval application, originally set for October 7, 2020. The delay allows the FDA to review additional data from the OCS Heart EXPAND trial. CEO Waleed Hassanein expressed disappointment but remains confident that the results will support FDA approval. The company specializes in portable organ preservation technologies aimed at enhancing organ transplantation outcomes.
TransMedics Group, Inc. (TMDX) reported a 40% decline in net revenue for Q2 2020, totaling $3.4 million compared to $5.7 million in Q2 2019, largely due to reduced organ transplant procedures amid the COVID-19 pandemic. The gross margin decreased to 56% from 59% year-over-year. Despite a net loss of $8.5 million, down from $9.2 million in the previous year, the company successfully raised $75 million in a public equity offering. TransMedics remains focused on advancing its OCS product initiatives with expected FDA approvals in 2021.
TransMedics Group, Inc. (Nasdaq: TMDX), a leader in organ transplant technology, will present at the Canaccord 40th Annual Growth Conference on August 13, 2020, at 10:00 a.m. EDT. This virtual event aims to highlight their innovations in portable organ preservation and assessment, which are critical for improving transplantation outcomes for patients with end-stage heart, lung, and liver failure. A live and archived webcast will be available on their website.
TransMedics Group, Inc. (TMDX) has announced that it will release its second-quarter financial results on August 5, 2020, after market close. The management team will host a conference call at 4:30 p.m. ET to discuss the results. Investors can join the call by dialing specific numbers for domestic and international callers. TransMedics specializes in portable extracorporeal warm perfusion technology, which improves organ transplant therapy for patients with end-stage organ failure.
TransMedics Group, Inc. (Nasdaq: TMDX) has announced a public offering of 5,000,000 shares of common stock at $14.00 per share, aiming for gross proceeds of $70 million. The offering is anticipated to close on May 29, 2020, subject to customary conditions. An additional 750,000 shares may be purchased by underwriters within 30 days. J.P. Morgan and Morgan Stanley lead the offering, with SEC registration effective since May 21, 2020. This initiative supports TransMedics' mission to enhance organ transplant therapies.
TransMedics Group, Inc. (TMDX) announced a public offering of $60 million in common stock, with J.P. Morgan and Morgan Stanley as joint lead managers. The offering may include an additional 15% to be purchased by underwriters. The effective shelf registration statement was filed with the SEC on May 21, 2020. This offering aims to enhance the company's capabilities in organ transplant technologies, addressing the need for improved organ preservation and viability assessment. Investors are cautioned regarding potential risks that may affect the offering's completion.
TransMedics (TMDX) announced positive results from its U.S. Pivotal OCS Liver PROTECT Trial, achieving primary and secondary endpoints related to liver transplantation. The trial demonstrated significantly lower early allograft dysfunction (17.3% OCS vs. 30.5% Control, p=0.009) and a high 30-day patient survival rate of 99.3%. Additionally, ischemic cholangiopathy incidences were reduced (1.4% OCS vs. 8.5% Control, p=0.005). A total of 155 donor livers were used, with a utilization rate of 98.1%. The trial's success marks a significant advancement in liver transplantation technology.